RESEARCH

Role of clinical pharmacists in epilepsy management at a general hospital in Vietnam: a before-and-after study

Hong Tham Pham1,2, Minh-Hoang Tran2, Ngoc Quy Nguyen3, Van Tan Vo4 and Manh Hung Tran2*

Abstract

Background: Clinical pharmacists have an important role in inter-professional healthcare collaboration for epilepsy management. However, the pharmacy practices of managing epilepsy are still limited in Vietnam, deterring pharmacists from routine adjustments of antiepileptic drugs, which could decrease the patients’ quality of life. This study aimed to assess the effectiveness of pharmacist interventions in epilepsy treatment at a Vietnamese general hospital.

Methods: A before-and-after study was conducted from January 2016 to December 2018. All patients with a diagnosis of epilepsy and being treated at the investigated hospital were recruited and screened for eligibility and exclusion criteria. The primary outcome was the proportion of patients in good control of their epilepsy (with two seizures or less in a year). The secondary outcome was the number of patients maintaining optimized concentrations within the therapeutic range of carbamazepine (4–12 mg/L), phenytoin (10–20 mg/L), or valproic acid (50–100 mg/L). Collected data were analyzed using two proportions Z-test or Chi-square test.

Results: A total of 141 participants were enrolled in the study. While most patients were given lower prescribed daily doses than the recommendations from the World Health Organization, over 56% of the participants still experienced adverse drug effects. More than half of the patients received at least one pharmacists’ intervention, which increased by 25.0% the effectiveness of the therapy (p < 0.001) and by 14.6% the number of patients with optimized drug concentrations (p = 0.018).

Conclusion: Epilepsy management requires a multiple-stepped and comprehensive approach, with a focus on the health and safety of the patients. As part of the healthcare team, pharmacists need to engage at every stage to monitor the patient’s response and determine the most effective treatment with the fewest adverse drug reactions.

Trial registration ClinicalTrials.gov, NCT04967326. Registered July 19, 2021—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04967326

Keywords: Adverse drug reaction, Antiepileptic drug, Clinical pharmacist, Epilepsy, Vietnam

Background

Worldwide, the prevalence of epilepsy is about 6.38 per 1000 persons, and annually, the incident rate is estimated at 61.44 per 100,000 person-years [1]. This figure could be higher in countries with low or average incomes (138.99 per 100,000 person-years) [1]. The current primary treatment involves antiepileptic drugs (AEDs), which aim to prevent seizures with the fewest adverse...
events. However, this general treatment approach tends to show unpredictable effectiveness, adverse drug reactions (ADRs), and sometimes, inappropriate dosages. Moreover, in clinic-based cohorts, over one-third of patients experience drug-resistant epilepsy [2].

Phenytoin, carbamazepine, and valproic acid, which are among the first-generation AEDs, are prescribed in many countries around the world [3], including Vietnam. These agents have complicated pharmacokinetics [4], which may result in alterations in absorption, distribution, and metabolism. This means that, given the same dose, the serum concentration of each drug may vary between patients. The management of epilepsy, as a result, requires inter-professional collaboration to ensure therapeutic optimization. As healthcare professionals, clinical pharmacists play an important role in epilepsy management, which includes establishing a therapeutic drug monitoring (TDM) protocol, adjusting doses, monitoring ADRs, etc.

However, the clinical pharmacy practices in epilepsy management are quite limited in Vietnam. The treatment gap—the proportion of people with epilepsy who are not adequately treated—still remains very high, especially in rural areas (84.7%), which probably results from discontinuing the treatment or refusing to take medications [5]. This shows a need for pharmacist consultations for patients with epilepsy and their family members, as they may be lack information about AEDs or motivation in controlling potential seizures. In addition, the adjustments of antiepileptic drugs by pharmacists are not routine procedures, nor are monitored for effectiveness in many Vietnamese hospitals. This lack of engagement threatens the patients’ safety and decreases their quality of life. To address this issue, certain interventions are needed to enable pharmacists to manage patients with epilepsy more systematically. This study was therefore conducted to evaluate the effectiveness of pharmacist interventions in epilepsy treatment at a general hospital in Vietnam.

**Methods**

**Study design and participants**

Nhan Dan Gia Dinh (NDGD) Hospital is a general hospital under the management of the Department of Health, Ho Chi Minh City, Vietnam, with about 1500 inpatient beds and 5000 outpatient visits per day. A before-and-after study was conducted in the Department of Neurology at NDGD Hospital from January 1, 2016 to December 31, 2018.

All patients with a diagnosis of epilepsy and being treated at NDGD Hospital from January 1, 2016 to January 1, 2017 were recruited. Patients were eligible if they (1) were prescribed a monotherapy or polytherapy of phenytoin (PHT), carbamazepine (CBZ), or valproic acid (VPA), and (2) were treated for more than one month. Patients were excluded if they (1) were pregnant or breastfeeding women; (2) had a history of alcoholism; (3) had liver or renal disease; and (4) were using drugs known to have an influence on cytochrome P450 (CYP450) enzymes.

The required sample size was calculated using the online tool Calculator.net [6], with a confidence level of 95%, 5% margin of error, and an approximate population size of 250 epileptic patients being treated at NDGD Hospital per year with either PHT, CBZ, or VPA. Following our survey on patients with epilepsy in 2016, without any healthcare interventions, about 63% had good seizure control. We estimated that for the pharmacist interventions to be clinically significant, at least 75% of the patients would need to have good seizure control by these implementations, resulting in a minimum sample size of 135 patients.

In the first period, before implementing the pharmacist interventions, patients were screened for demographic characteristics, drug serum concentration, and information about previous treatments. After the interventions, patients were followed up for one year, and at the study endpoint, patients were screened again for the study outcomes.

**Intervention**

Following blood sample collection, the clinical pharmacist interventions were carried out, involving TDM for each patient to optimize their AED therapy. This optimization involved either medication consultation, dosage adjustment, medication switching/discontinuation, or combination therapy, based on the serum concentration of AEDs and the patient’s ADRs. Only patients whose blood samples or clinical manifestations revealed unoptimized regimens were assigned to the subsequent optimization interventions. All the physicians and pharmacists involved had reached a consensus on the relevant interventions.

**Outcomes**

The primary outcome was the effectiveness of the AED therapy, measured by the number of seizures during the first year of the study and during the year prior to the study endpoint. Patients with two seizures or less in a year were categorized as having good control, whereas those who had more were considered to have poor control. The secondary outcome was the number of patients who maintained an optimized concentration of AED. The targeted therapeutic ranges for CBZ, PHT, and VPA were 4–12 mg/L, 10–20 mg/L, and 50–100 mg/L, respectively.
Statistical analysis
Data collected from medical records were presented as means with standard deviation (SD) or median with interquartile range (Q1–Q3) for continuous variables or as frequencies with percentages for categorical variables. Differences in proportion were analyzed using the two proportion Z-test or the Chi-square test. Best–worst case analyses were also conducted to control for potential bias due to loss to follow-up. All hypotheses were carried out with a confidence level of 95%. The analyses were performed using the Statistical Package for Social Sciences software, version 25.0 (SPSS Inc., Chicago, Illinois, United States).

Ethics approval
This study was approved by the NDGD Hospital Ethics Committee, Ho Chi Minh City, Vietnam, with approval number 23-2015/CN-HĐĐĐ, on October 13, 2015. The patients included all gave their informed consent.

Results
Demographic characteristics of the participants
A total of 141 epileptic patients were enrolled in the study, as shown in Fig. 1.

The characteristics of the study participants are shown in Table 1. Of the 141 participants, the median age was 54, ranging from 16 to 81 years old. The median body weight was 58 kg, with 34.8% being overweight or obese. About 40% of the patients have undergone treatment with AEDs for more than 10 years. The most favored

| Characteristics | Value (N = 141) |
|-----------------|----------------|
| Gender, n (%)   |                |
| Female          | 59 (41.8)      |
| Male            | 82 (58.2)      |
| Age (years), median (Q1–Q3) | 54 (38–61) |
| Body weight (kg), median (Q1–Q3) | 58 (52–65) |
| Body mass index (kg/m²), mean ± SD | 22.2 ± 2.8 |
| < 23, n (%)     | 92 (65.2)      |
| ≥ 23, n (%)     | 49 (34.8)      |
| Duration of treatment, n (%) |        |
| < 5 years       | 68 (42.2)      |
| 5–10 years      | 24 (17.0)      |
| > 10 years      | 49 (40.8)      |
| AED therapy, n (%) |            |
| Monotherapy     | 99 (70.2)      |
| Polytherapy     | 42 (29.8)      |

Table 1 Demographic characteristics of patients with epilepsy at the start of the study (N = 141)

Q1–Q3 interquartile range, SD standard deviation, AED antiepileptic drug

Fig. 1 Flow diagram of the study participants
Characteristics of AED therapy

The defined daily dose (DDD) and prescribed daily dose (PDD) for AEDs are summarized in Table 2. It is evident that the average PDD for all three AEDs was much lower than the DDD recommended by the World Health Organization (WHO) [7]. Phenytoin was the drug with the highest proportion of PDD/DDD in both monotherapy and polytherapy. Patients on monotherapy received a less dispersed and lower PDD compared to those taking multiple AEDs.

Table 2 Dosage of carbamazepine, valproic acid, and phenytoin at the start of the study

|                      | Carbamazepine (n = 64) | Valproic acid (n = 65) | Phenytoin (n = 29) |
|----------------------|------------------------|------------------------|--------------------|
| DDD (mg)             | 1000                   | 1500                   | 300                |
| Monotherapy, n       | 40                     | 38                     | 21                 |
| PDD (mg), mean ± SD  | 446 ± 216              | 669 ± 277              | 213 ± 46           |
| %DDD                 | 44.6                   | 44.6                   | 70.8               |
| Polytherapy, n       | 24                     | 27                     | 8                  |
| PDD (mg), mean ± SD  | 587 ± 456              | 972 ± 528              | 225 ± 50           |
| %DDD                 | 58.7                   | 64.8                   | 75.0               |

*a DDD: defined daily dose, retrieved from https://www.whocc.no/atc_ddd_index
*b PDD: prescribed daily dose
*c %DDD = PDD/DDD

Table 3 Adverse drug reactions to AED therapy (N = 141)

| Adverse drug reactions (ADRs) | Monotherapy (n = 99) | Polytherapy (n = 42) | p-value |
|-------------------------------|----------------------|----------------------|---------|
| No symptoms of ADRs, n (%)    | 45 (45.5)            | 16 (38.1)            | 0.420*  |
| Experienced ADRs, n (%)       | 54 (54.5)            | 26 (61.9)            |         |
| Dizziness or headache         | 20 (20.2)            | 12 (28.6)            |         |
| Sleep disorders               | 24 (24.2)            | 9 (21.4)             |         |
| Weight gain                   | 7 (7.1)              | 3 (7.1)              |         |
| Depression                    | 2 (2.0)              | 2 (4.8)              |         |
| Itchiness or rash             | 9 (9.1)              | 4 (9.5)              |         |
| Others                        | 32 (32.3)            | 16 (38.1)            |         |

*Chi-square test; the ADRs were recorded until there was a loss to follow-up.

Clinical pharmacist interventions

Table 4 indicates the interventions of the clinical pharmacists. By the end of the study, 109 interventions had been carried out for 74 patients (52.5%). Patients with serum concentrations of AEDs outside the therapeutic range were more likely to receive medication modifications. Dosage adjustment accounted for the largest proportion (43/109 interventions). In these cases, patients encountering mild or moderate ADRs had their doses...
decreased, while those with poor seizure control were adjusted to higher doses of AEDs. Patients with uncontrolled seizures or refractory epilepsy were also given additional or alternative drugs with better efficacy (levetiracetam, oxcarbazepine, etc.). Those with major-severe ADRs (i.e., dermatologic or hepatic effects) were either switched to newer generation AEDs with safer profiles (topiramate, levetiracetam, etc.) or discontinued from their current medications. Pharmacists also counseled patients to improve their adherence to the therapy and to instruct initial steps to manage any possible ADRs.

**Effectiveness of pharmacist interventions**

The effects of the pharmacists’ interventions are reported in Table 5. Before implementing the interventions, 56% of the patients had good seizure control, and the drug serum concentrations of 51.8% of patients were within the therapeutic range. At the study endpoint, 17.7% of the participants were lost to follow-up. The proportion of patients in good control of their seizures had increased significantly to 81%. The TDM for AEDs was carried out again, showing that 66.4% of patients had maintained stable serum concentrations. Given the considerable percentage of loss to follow-up, the best–worst case analyses were conducted. In the worst-case scenario, there were no differences in the drug serum concentration ($p=0.633$) or in the number of patients with good seizure control ($p=0.067$). In contrast, in the best-case scenario, the interventions had improved both the treatment effectiveness and the patients’ medication blood levels ($p<0.001$).

**Discussion**

Epilepsy management is a complicated process, and the outcomes can be hard to predict. The main target is to achieve a seizure-free status without significant adverse effects [9]. A proper treatment strategy is critical for controlling seizures and for minimizing possible ADRs. This study showed that CBZ (45.4%) and VPA (46.1%) were prescribed more frequently than PHT (18.4%) for epilepsy treatment. In many countries, phenytoin is no longer a first-line therapy due to concerns over its adverse effects [10], which partly explains why it was given less frequently to epileptic patients in this study. Many guidelines now recommend the use of monotherapy with AED for most patients because of similar efficacy and better

Table 5 Analysis of the outcomes at the study endpoint

|                          | Before interventions | After interventions | $p$-value |
|--------------------------|----------------------|---------------------|-----------|
|                          | Monotherapy ($n=99$) | Polytherapy ($n=42$) | Total ($N=141$) | Monotherapy ($n=79$) | Polytherapy ($n=37$) | Total ($N=116$) |         |
| Treatment effectiveness, n (%) |                      |                     |             |                      |                     |             |         |
| Good control             | 61                   | 18                  | 79 (56.0)   | 66                   | 28                  | 94 (81.0)   | $<0.001^*$ |
| Poor control             | 38                   | 24                  | 62 (44.0)   | 13                   | 9                   | 22 (19.0)   |           |
| Drug serum concentration, n (%) |                      |                     |             |                      |                     |             |         |
| Within therapeutic range | 57                   | 16                  | 73 (51.8)   | 53                   | 24                  | 77 (66.4)   | 0.018*    |
| Outside therapeutic range| 42                   | 26                  | 68 (48.2)   | 26                   | 13                  | 39 (33.6)   |           |

Worst and best case analysis

|                          | Total ($N=141$) | Total ($N=141$) |         |
|--------------------------|----------------|----------------|-----------|
| Worst case               |                |                |           |
| Treatment effectiveness, n (%) |                |                |           |
| Good control             | –              | –              | 79 (56.0) | –              | –              | 94 (66.7)   | 0.067*    |
| Poor control             | –              | –              | 62 (44.0) | –              | –              | 47 (33.3)   |           |
| Drug serum concentration, n (%) |                |                |           |
| Within therapeutic range | –              | –              | 73 (51.8) | –              | –              | 77 (56.0)   | 0.633*    |
| Outside therapeutic range| –              | –              | 68 (48.2) | –              | –              | 64 (44.0)   |           |
| Best case                |                |                |           |
| Treatment effectiveness, n (%) |                |                |           |
| Good control             | –              | –              | 79 (56.0) | –              | –              | 119 (84.4)  | $<0.001^*$ |
| Poor control             | –              | –              | 62 (44.0) | –              | –              | 22 (15.6)   |           |
| Drug serum concentration, n (%) |                |                |           |
| Within therapeutic range | –              | –              | 73 (51.8) | –              | –              | 102 (73.8)  | $<0.001^*$ |
| Outside therapeutic range| –              | –              | 68 (48.2) | –              | –              | 39 (26.2)   |           |

*Chi-square test, conducted between the total before and after the interventions
tolerability compared to polytherapy [11]. As reported in some prior studies, the proportion of monotherapy is pretty high and can be up to 71% [12, 13]. This study’s result also showed a preference for monotherapy in over 70% of the patients. However, there is still a need for evidence-based guidelines for an overall optimal recommended initial monotherapy with AED [14], and further research should be conducted to identify influential factors in the effectiveness of AED monotherapy.

In terms of dosage, there is a noticeable difference between the recommendations of the WHO and the clinical practice in many countries, as reflected in previous publications [12, 15]. The majority of these studies report a lower PDD than the recommended DDD. A reason for this may be that many AEDs can cause dose-related neurotoxic adverse reactions, so to mitigate these effects, monotherapy, with the lowest effective dose, should be applied for all patients whenever possible [16]. Despite this discrepancy, the PDD/DDD ratio (or %DDD) could be a significant indicator of subsequent outcomes. When the seizures of a patient using their first AED at a dose above 50% or 75% of DDD were uncontrolled, the patient had a lower probability of being seizure-free at the last follow-up ($p < 0.001$) [17]. When considering an appropriate dose for defining treatment failure [17, 18], the threshold of either 50% or 75% of DDD could be applied in a definition of refractory epilepsy [17].

In epilepsy treatment, mitigation of ADRs is a critical target for all patients. This study’s results showed that 56.7% of patients experienced ADRs when undergoing AED therapy, a result which is similar to that of a study investigating the ADRs of newer AEDs in Germany, where 56.6% of patients were reported with ADRs [19]. Findings from the literature suggest that newer AEDs may have better tolerability and safety than older generation medications, i.e., carbamazepine, phenytoin, and valproic acid [20]. Despite this, the similarity in prevalence between these two sets of ADR could possibly have resulted from the interventions of the clinical pharmacists in our study, which aimed to minimize the adverse effects of AEDs. Furthermore, the question of whether monotherapy or polytherapy is associated with more ADRs is still controversial [19]. Although in this study, the two types of therapy did not differ significantly in terms of adverse reactions, evidence from previous research indicates a higher risk of side effects in patients on polymedication regimens [16, 21].

Epilepsy management may involve engagement from many sides, including healthcare professionals and family members of the patients. As medication therapy is the most favored approach in controlling seizures [22], the role of the clinical pharmacist is explicitly important. Medical staff usually have to consider the trade-off between epilepsy control and the minimization of possible ADRs. This requires inter-professional involvement if it is to ensure the best treatment for all patients. As a member of the healthcare team, the clinical pharmacist can engage in counseling therapeutic compliance, TDM of AEDs, monitoring drug interactions and ADRs, and adjusting dosage and medications. Based on these functions, this study implemented critical interventions to optimize therapy for patients with epilepsy. In the course of this, dosage adjustment was carried out for 39.4% of patients. This figure is comparable to the results of a study in Thailand (2004), in which 38.9% of patients received pharmacists’ recommendations for adjusting their dosage regimens [23]. About 15% of the patients in our study received additional AEDs due to poor control of seizures and the intolerability of dose-increased medications. Our pharmacists tried to keep this proportion minimal to lower the risks of ADRs to the patients.

The pharmacists’ interventions in this study showed positive changes in epilepsy management and the serum concentration of AEDs. Although 17.7% of the participants were lost to TDM follow-up, after performing a best–worst-case analysis, at the very least, the interventions did not worsen the patients’ drug blood levels or condition. In the more optimistic scenario, most of the patients benefitted from the implementation of the intervention. This finding agrees with previous studies that have stressed the importance of clinical pharmacists being involved in epilepsy management [22, 24].

TDM is a useful tool by which to evaluate the potential causes of toxicity, lack of efficacy, or loss of efficacy [9]. A clinical pharmacist can help optimize this procedure by requesting TDM when necessary, giving instructions on when and how to collect samples for the TDM, and then adjusting dosage based on the TDM results. However, TDM is not a “golden key” in managing epilepsy. The therapeutic ranges for AED are derived from the whole population, while individuals might need a lower or higher dose of AED therapy to control their seizures [16]. Therefore, pharmacists should not depend solely on TDM results to adjust the dosage or change the medication, but multiple factors, especially the patient’s response, must also be considered before the final decision is reached [25].

Combining with other findings from some low- and middle-income countries [23, 26–28], we had suggested some strategies to assist clinical pharmacists in these regions to overcome challenges from epilepsy management. First, in addition to regularly counseling patients, pharmacists should also actively engage and implement educational programs to improve patients’ knowledge and perception of epilepsy [26]. Second, pharmacists should focus on routine TDM of AEDs to maximize its
benefits and cost-effectiveness [27, 28], which could improve the treatment efficacy and seizure control [23]. Noticeably, as TDM is a multidisciplinary approach [23], this practice can also enhance the inter-professional collaboration among medical staff, thus increasing the overall healthcare quality of the treatment facilities. Finally, in countries where the access to newer AEDs is limited, pharmacists should engage with physicians to optimize the available therapy—either in dosage through TDM or in AED choice through combining/switching medications—to ensure the rational treatment for their patients.

In addition to its helpful findings, this study also has certain limitations. First, the TDM procedure could only be carried out twice for each patient. All other differences in drug concentrations during the study were not recorded, and the final assessment may therefore not be the best reflection of the true effectiveness of the interventions. Second, the outcomes were measured mainly in relation to the number of seizures, while other important factors, such as hospital readmission or quality of life, were not taken into account.

Conclusion
Management of epilepsy requires many steps, with a focus on the health and safety of the patients. A comprehensive approach should be applied to optimize the treatment for all patients, from monitoring the drug concentration and potential adverse effects to adjusting dosage and switching medications whenever needed. As a part of the healthcare team and with a critical role to play in epilepsy management, pharmacists need to engage in every stage to monitor the patient’s response and to determine the most effective treatment with the fewest ADRs.

Abbreviations
ADR: Adverse drug reaction; AED: Antiepileptic drug; CBZ: Carbamazepine; DDD: Defined daily dose; NDGD: Nhan Dan Gia Dinh; PDD: Prescribed daily dose; PHT: Phenytoin; TDM: Therapeutic drug monitoring; VPA: Valproic acid; WHO: World Health Organization.

Acknowledgements
The authors would like to express their gratitude to the staff of Nhan Dan Gia Dinh Hospital for assisting data collection process.

Authors’ contributions
HTP, M-HT, and MHT designed the study and the methodology. HTP, NQN, and VTV collected the data. HTP and M-HT conducted statistical analyses and drafted the manuscript. MHT finalized the manuscript and supervised the study. All authors have read and approved the final manuscript.

Funding
This study was not funded by any organizations.

Availability of data and materials
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Nhan Dan Gia Dinh Hospital Ethics Committee, Ho Chi Minh City, Vietnam, with approval number 23-2015/CN-HDSD, on October 13, 2015. The patients included all gave their informed consent.

Competing interests
The authors declare that they have no competing interests relevant to the study.

Author details
1 Department of Pharmacy, Nhan Dan Gia Dinh Hospital, Ho Chi Minh City, Vietnam. 2 Department of Pharmacology, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, 41–43 Dinh Tien Hoang Street, Ben Nghe Ward, District 1, Ho Chi Minh City, Vietnam. 3 Institute of Environmental Sciences, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam. 4 Department of Neurology, Nhan Dan Gia Dinh Hospital, Ho Chi Minh City, Vietnam.

Received: 8 September 2021 Accepted: 14 December 2021

Published online: 20 December 2021

References
1. Fiest KM, Sauro KM, Wiebe S, Patton SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296–303. https://doi.org/10.1212/WNL.0000000000003509.
2. Sultana B, Panzini M-A, Veilleux Carpentier A, Comtois J, Rious B, Gore G, et al. Incidence and prevalence of drug-resistant epilepsy. Neurology. 2021;96(17):805–17. https://doi.org/10.1212/WNL.000000000018139.
3. Huang YH, Chi NF, Kuan YC, Chan L, Hu CJ, Chiou HY, et al. Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. Eur J Neurol. 2015;22(11):1459–68. https://doi.org/10.1111/ene.12766.
4. Halvorsen KH, Johannessen Landmark C, Granas AG. Prevalence of different combinations of antiepileptic drugs and CNS drugs in elderly home care service and nursing home patients in Norway. Epilepsy Res Treat. 2016. https://doi.org/10.1155/2016/5153093.
5. Tuan NA, Tomson T, Allebeck P, Chuc NTK, Cuong LQ. The treatment gap of epilepsy in a rural district of Vietnam: a study from the EPIBAVI project. Epilepsia. 2009;50(10):2320–3. https://doi.org/10.1111/j.1528-1167.2009.02298.x.
6. Calculator.net. https://www.calculator.net/sample-size-calculator.html. Accessed 15 Sep 2015.
7. Grimmsmann T, Himmel W. Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? Eur J Clin Pharmacol. 2011;67(8):847–54. https://doi.org/10.1007/s00228-011-1014-7.
8. Wang Q, Zhou IJ, Zhou LM, Chen ZY, Fang ZY, Chen SD, et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011;20(6):446–8. https://doi.org/10.1016/j.seizure.2011.02.003.
9. Panayiotopoulos CP. Principles of therapy in epilepsy. In: Panayiotopoulos CP, editor. The epilepsies—seizures, syndromes and management. Oxfordshire: Bladon Medical Publishing, 2005.
10. Nevitt SJ, Manson AG, Weston J, Tudur SC. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2017;2(2):CD001911. https://doi.org/10.1002/14651858.CD001911.pub3.
11. St Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009;7(2):77–82. https://doi.org/10.2174/157015909788848866.
12. Hsieh LP, Huang CY. Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database. Epilepsia. 2009;50(1):21–7. https://doi.org/10.1111/j.1528-1167.2008.01108.x.
13. Nasir BB, Yifru YM, Engidawork E, Gebrewold MA, Woldu MA, Berha AB. Antiepileptic drug treatment outcomes and seizure-related injuries among adult patients with epilepsy in a tertiary care hospital in Ethiopia.
14. Glauzer T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–120. https://doi.org/10.1111/j.1528-1167.2006.00585.x.

15. Horvath L, Fekete K, Martron S, Fekete I. Correlation between prescribed daily dose, seizure freedom and defined daily dose in antiepileptic drug treatment. Int J Clin Pharm. 2017;39(2):459–67. https://doi.org/10.1007/s11096-017-0447-1.

16. St Louis EK. Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care. Curr Neuropsychopharmacol. 2009;7(2):106–14. https://doi.org/10.2174/157015909788848857.

17. Brodie MJ, Barry SJ, Bamagous GA, Kwan P. Effect of dosage failed of first antiepileptic drug on subsequent outcome. Epilepsia. 2013;54(1):194–8. https://doi.org/10.1111/epi.12322.

18. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77. https://doi.org/10.1111/j.1528-1167.2009.02397.x.

19. Hilgiers A, Schaefer M. Systematic adverse drug reaction monitoring of patients under newer antiepileptic drugs using routine clinical data of inpatients. Drugs Real World Outcomes. 2016;3(2):209–21. https://doi.org/10.1007/s40801-016-0077-2.

20. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141–58. https://doi.org/10.1177/2042098611411127.

21. Carpay JA, Aldenkamp AP, van Donselaar CA. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure. 2005;14(3):198–206. https://doi.org/10.1016/j.seizure.2005.01.008.

22. Koshy S. Role of pharmacists in the management of patients with epilepsy. Int J Pharm Pract. 2012;20(1):65–8. https://doi.org/10.1111/j.2042-7174.2011.00156.x.

23. Lertsinudom S, Chaiyakum A, Tuntapakul S, Sawanyawisuth K, Tiamkao S, Tiamkao S, et al. Therapeutic drug monitoring in epilepsy clinic: a multidisciplinary approach. Neurol Int. 2014;6(4):83–5. https://doi.org/10.4081/ni.2014.5620.

24. Reis T, Campos M, Nagai M, Pereira L. Contributions of pharmacists in the treatment of epilepsy: a systematic review. Am J Pharm Benefits. 2016;8(3):e55–60.

25. Azar NJ, Abou-Khalil BW. Considerations in the choice of an antiepileptic drug in the treatment of epilepsy. Semin Neurol. 2008;28(3):305–16. https://doi.org/10.1055/s-2008-1079335.

26. Eshiet U, Okonta J, Ukwe C. The efficacy of a pharmacist implemented educational treatment programme for people with epilepsy: a report of a randomised controlled trial. Seizure. 2019;69:147–53. https://doi.org/10.1016/j.seizure.2019.04.011.

27. Rane CT, Dalvi SS, Gogray NJ, Shah PU, Kishirsagar NA. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol. 2001;52(2):193–5. https://doi.org/10.1046/j.0306-5251.2001.01436.x.

28. Ratanajamit C, Kaewpibal P, Sethawacharavanich S, Farooqnsang D. Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs. J Med Assoc Thai. 2009;92(11):1500–7.